清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer

CCL19型 免疫疗法 医学 三阴性乳腺癌 免疫系统 树突状细胞 乳腺癌 肿瘤微环境 CD8型 癌症研究 免疫学 癌症免疫疗法 肿瘤科 癌症 内科学 趋化因子 趋化因子受体
作者
Siyu Wu,Si-Wei Zhang,Ding Ma,Yi Xiao,Liu Yin,Li Chen,Xiao-Qing Song,Xiao-Yan Ma,Ying Xu,Wen-Jun Chai,Xi Jin,Zhi-Ming Shao,Yi‐Zhou Jiang
出处
期刊:Med [Elsevier]
卷期号:4 (6): 373-393.e8 被引量:6
标识
DOI:10.1016/j.medj.2023.04.008
摘要

Background The extensive involvement of dendritic cells (DCs) in immune contexture indicates their potent value in cancer immunotherapy. Understanding DC diversity in patient cohorts may strengthen the clinical benefit of immune checkpoint inhibitors (ICIs). Methods Single-cell profiling of breast tumors from two clinical trials was performed to investigate DC heterogeneity. Multiomics, tissue characterization, and pre-clinical experiments were used to evaluate the role of the identified DCs in the tumor microenvironment. Four independent clinical trials were leveraged to explore biomarkers to predict ICI and chemotherapy outcomes. Findings We identified a distinct CCL19-expressing functional state of DCs associated with favorable responses to anti-programmed death (ligand)-1 (PD-(L)1), which displayed migratory and immunomodulatory phenotypes. These cells were correlated with antitumor T cell immunity and the presence of tertiary lymphoid structures and lymphoid aggregates, defining immunogenic microenvironments in triple-negative breast cancer. In vivo, CCL19+ DC deletion by Ccl19 gene ablation dampened CCR7+CD8+ T cells and tumor elimination in response to anti-PD-1. Notably, high circulating and intratumoral CCL19 levels were associated with superior response and survival in patients receiving anti-PD-1 but not chemotherapy. Conclusions We uncovered a critical role of DC subsets in immunotherapy, which has implications for designing novel therapies and patient stratification strategies. Funding This study was funded by the National Key Research and Development Project of China, the National Natural Science Foundation of China, the Program of Shanghai Academic/Technology Research Leader, the Natural Science Foundation of Shanghai, the Shanghai Key Laboratory of Breast Cancer, the Shanghai Hospital Development Center (SHDC), and the Shanghai Health Commission.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嘿嘿完成签到 ,获得积分10
10秒前
zeannezg完成签到 ,获得积分10
18秒前
俊俊完成签到 ,获得积分0
20秒前
2024kyt完成签到 ,获得积分10
34秒前
43秒前
司马绮山完成签到,获得积分10
45秒前
张小汉发布了新的文献求助10
48秒前
张peter完成签到 ,获得积分10
53秒前
56秒前
liu95完成签到 ,获得积分10
58秒前
摘星012完成签到 ,获得积分10
1分钟前
xianyaoz完成签到 ,获得积分10
1分钟前
NN完成签到,获得积分10
1分钟前
张小汉发布了新的文献求助10
1分钟前
1分钟前
无悔完成签到 ,获得积分10
1分钟前
张小汉完成签到,获得积分10
1分钟前
mito完成签到,获得积分10
1分钟前
莎莎完成签到 ,获得积分10
1分钟前
elisa828完成签到,获得积分10
1分钟前
Dr.Zhang应助科研通管家采纳,获得30
1分钟前
spark810应助科研通管家采纳,获得30
1分钟前
spark810应助科研通管家采纳,获得30
1分钟前
Singularity应助科研通管家采纳,获得20
1分钟前
康复小白完成签到 ,获得积分10
1分钟前
yueLu完成签到 ,获得积分10
1分钟前
橘子海完成签到 ,获得积分10
1分钟前
小小果妈完成签到 ,获得积分10
2分钟前
skp发布了新的文献求助10
2分钟前
无辜的行云完成签到 ,获得积分0
2分钟前
2分钟前
宇文雨文完成签到 ,获得积分10
2分钟前
今后应助mm_zxh采纳,获得10
2分钟前
小伊001完成签到,获得积分10
2分钟前
2分钟前
尔信完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
凤凰之玉发布了新的文献求助200
3分钟前
hamster完成签到,获得积分10
3分钟前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Gerard de Lairesse : an artist between stage and studio 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3081598
求助须知:如何正确求助?哪些是违规求助? 2734439
关于积分的说明 7532820
捐赠科研通 2383917
什么是DOI,文献DOI怎么找? 1264125
科研通“疑难数据库(出版商)”最低求助积分说明 612563
版权声明 597578